Welcome, Guest. Please login or register.
December 01, 2023, 08:37:29 am

Login with username, password and session length

  • Total Posts: 55103
  • Total Topics: 4849
  • Online Today: 106
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 43
Total: 43


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA OKs 8 Weeks of Mavyret for Hep C Treatment First-Timers  (Read 4275 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
FDA OKs 8 Weeks of Mavyret for Hep C Treatment First-Timers
« on: October 23, 2019, 10:32:15 am »
The Food and Drug Administration (FDA) has granted a new approval of AbbVie’s Mavyret (glecaprevir/pibrentasvir) that shortens treatment from 12 to eight weeks for those with all six genotypes of hepatitis C virus (HCV) who have not been treated previously. The new drug indication applies to adults and to children who are at least 12 years old or weigh at least 99 pounds and to those without cirrhosis or who have compensated cirrhosis, the milder form of the severe liver disease.

Mavyret was first approved in 2017.

The new indication for Mavyret makes it the first regimen approved for an eight-week course among treatment first-timers and certain children and adolescents with genotypes 1 through 6 of HCV who have compensated cirrhosis or who do not have cirrhosis.



© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.